Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts.
about
Late and chronic antibody-mediated rejection: main barrier to long term graft survivalIssues in solid-organ transplantation in children: translational research from bench to bedside.Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.Diagnosis and management of antibody-mediated rejection: current status and novel approaches.Immunologic and non-immunologic complications of a third kidney transplantation.The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients.Desensitization for prevention of chronic antibody-mediated rejection after kidney transplantation.Donor-Specific Antibodies in Kidney Transplant Recipients.Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab.Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppression.Transplant glomerulopathy.Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation.Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejectionTreatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results
P2860
Q27006030-BBBB30CE-1649-4BF7-AEC9-B7249806C19BQ27023312-DD2C4EAC-9D0B-4EE4-8965-7EEA5F1294FAQ33891669-4BE74B4B-F244-46AF-8899-DC7A1F41D389Q34841849-05D1DEB0-BEBD-412F-988D-A84E4213FFACQ36081212-8B4665FC-F6DC-48DC-9F4F-FD502AECE273Q37704938-5EEF7F01-B87B-4D59-956B-7E9340A274AFQ38168293-85EB9CBD-0803-413A-B9A8-CB6936399A0AQ39265221-0480E3E7-3ABB-49EF-8DD4-FB05E7431E82Q40149564-3ADB5602-ED80-495C-9E16-FCA344E2834CQ47773036-3F6B7E3D-3B90-4894-A711-6FD1D694114EQ50063069-45A70685-2808-40E8-B5E0-E6A1CB0C4D41Q51002006-B8F8063F-5CF9-41E1-A8C2-8A1B18251820Q52656964-C2047937-B1A9-49B5-8C5E-EAFF0B8C270EQ57474736-9DB56C2D-FF29-4DEF-B230-A553927A4C58Q58754949-164E882F-90C5-4035-9934-4B82C51BB4D6
P2860
Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 August 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Partial therapeutic response t ...... ejection of kidney allografts.
@en
Partial therapeutic response t ...... ejection of kidney allografts.
@nl
type
label
Partial therapeutic response t ...... ejection of kidney allografts.
@en
Partial therapeutic response t ...... ejection of kidney allografts.
@nl
prefLabel
Partial therapeutic response t ...... ejection of kidney allografts.
@en
Partial therapeutic response t ...... ejection of kidney allografts.
@nl
P2093
P2860
P1476
Partial therapeutic response t ...... rejection of kidney allografts
@en
P2093
Emmanuel Zorn
Fahim Malik
Nelson Goes
Nina Tolkoff-Rubin
R Neal Smith
Sonika Puri
Susan Saidman
Waichi Wong
P2860
P304
P356
10.1016/J.TRIM.2012.08.005
P577
2012-08-30T00:00:00Z